Walleye Capital
LVTX

Walleye Capital’s LAVA Therapeutics LVTX Stock Holding History

Walleye Capital’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,762
Closed -$24.5K – 5243
2024
Q3 		$24.5K Sell
14,762
-10,913
-43% -$20K ﹤0.01% 4778
2024
Q2 		$46.2K Sell
25,675
-128,991
-83% -$341K ﹤0.01% 4944
2024
Q1 		$515K Buy
+154,666
New +$340K ﹤0.01% 3165

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Walleye Capital's LVTX Position: Q4 2024 in Review

Walleye Capital sold out of LAVA Therapeutics (LVTX) in Q4 2024, closing a stake of 14,762 shares — an estimated $24.5K sold.

Walleye Capital first reported a position in LVTX in Q1 2024 and held it in 3 quarters. The position peaked at $515K in Q1 2024. 22 funds tracked by Wall St. Rank hold LVTX as of Q4 2024.

  • Walleye Capital reported no remaining LAVA Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 14,762 LAVA Therapeutics shares in Q4 2024, an estimated $24.5K.
  • Walleye Capital first reported a position in LAVA Therapeutics in Q1 2024 and held it in 3 quarters.
  • Walleye Capital's LAVA Therapeutics position peaked at $515K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.